News
AIM
0.3649
+2.39%
0.0085
Weekly Report: what happened at AIM last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at AIM last week (0708-0712)?
Weekly Report · 07/15 10:17
AIM ImmunoTech files to sell 11.28M shares of common stock for holders
AIM ImmunoTech files to sell 11.28M shares of common stock for holders Jul. 11, 2024 6:00 PM ETAIM immunoTech Inc. Filed a prospectus related to the offer and resale of up to 11,281,916 shares.
Seeking Alpha · 07/11 22:00
Weekly Report: what happened at AIM last week (0701-0705)?
Weekly Report · 07/08 10:18
Weekly Report: what happened at AIM last week (0624-0628)?
Weekly Report · 07/01 10:18
Weekly Report: what happened at AIM last week (0617-0621)?
Weekly Report · 06/24 10:22
Weekly Report: what happened at AIM last week (0610-0614)?
Weekly Report · 06/17 10:17
Weekly Report: what happened at AIM last week (0603-0607)?
Weekly Report · 06/10 10:18
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM ImmunoTech Inc. Will participate in the Virtual Investor Pitch Conference on Monday, June 17, 2024. Thomas K. Equels, MS JD, Chief Executive Officer of AIM will attend the conference. The conference will be held in New York City, New York.
Barchart · 06/10 07:55
Weekly Report: what happened at AIM last week (0527-0531)?
Weekly Report · 06/03 10:20
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
AIM ImmunoTech Inc. Will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET. Thomas K. Equels, MS JD, Chief Executive Officer of AIM will be in attendance. AIM immunoTech is a leading biotech company.
Barchart · 06/03 08:15
Weekly Report: what happened at AIM last week (0520-0524)?
Weekly Report · 05/27 10:23
Weekly Report: what happened at AIM last week (0513-0517)?
Weekly Report · 05/20 10:19
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
Barchart · 05/20 08:15
Buy Rating Affirmed: AIM ImmunoTech’s Ampligen Shows Promising Oncology Pipeline Progress
TipRanks · 05/17 17:55
AIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024
AIM ImmunoTech reported earnings per share of -12 cents for the first quarter of 2024. The company reported revenue of $40,000. This was below the analyst estimate for EPS of -11 cents. AIM immunoTech is expected to report results for the second quarter of 2025.
Investorplace · 05/16 15:52
AIM ImmunoTech GAAP EPS of -$0.12
IM ImmunoTech Inc. Reports Q1 GAAP EPS of -$ . As of March 31, 2024, AIM reported cash, cash equivalents and marketable securities of $ million. AIM reports a GAAP quarterly loss of $ -$ 1.5 million.
Seeking Alpha · 05/16 11:33
*AIM ImmunoTech 1Q Loss $5.8M >AIM
Dow Jones · 05/16 11:30
Notable earnings before Thursday's open
Seeking Alpha · 05/15 15:47
AIM ImmunoTech Q1 2024 Earnings Preview
Seeking Alpha · 05/15 15:26
More
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.